T1	intervention 0 29	Ixabepilone plus capecitabine
T2	eligibility 697 741	anthracycline/taxane-pretreated MBC patients
T3	control 802 820	capecitabine alone
T5	total-participants 872 875	606
T6	total-participants 903 907	1349
T8	outcome 1196 1198	OS
T9	iv-cont-median 1208 1212	12.3
T10	cv-cont-mean 1217 1227	9.5 months
T13	outcome 1252 1255	PFS
T14	iv-cont-median 1265 1268	4.6
T15	cv-cont-median 1273 1283	3.1 months
T19	iv-bin-percent 1316 1318	35
T20	cv-bin-percent 1323 1326	19%
T21	outcome 1434 1443	median OS
T22	iv-cont-median 1447 1451	16.7
T23	cv-cont-median 1459 1470	16.2 months
T26	outcome 1495 1505	median PFS
T27	iv-cont-median 1509 1512	6.0
T28	cv-cont-median 1520 1530	4.4 months
T32	iv-bin-percent 1566 1568	45
T33	cv-bin-percent 1576 1579	28%
T34	outcome 1585 1599	safety profile
T7	outcome 1559 1562	ORR
T12	outcome 1311 1314	ORR
